新聞Jenkins leaves Dimension Therapeutics, Inc as chief executive officer.Dr Jenkins joins the company from Dimension Therapeutics, where she served as its chief executive officer, and her previous roles have seen her gain expertise in scientific research, clinical development, regulatory process and commercialisation.
新聞Dimension Therapeutics, Inc partnered with REGENXBIO Inc. on Aug 1st '17.Cambridge-based Dimension had entered a merger agreement with Regenxbio, announced in August.
新聞Dimension Therapeutics, Inc decreased headcount by 74 on Jun 1st '17.In June, after scrapping its lead drug due to disappointing trial results, Dimension announced plans to cut its workforce from 74 employees to around 56 by year-end, but the company has repeatedly declined to disclose its headcount during the negotiations.
